Margarita Dominguez-Villar, PhD
DownloadHi-Res Photo
About
Education & Training
- Postdoctoral Associate
- Yale School of Medicine (2012)
- Postdoctoral Associate
- Harvard Medical School and Brigham and Women's Hospital (2010)
- PhD
- University of Cadiz (2007)
- Postdoctoral Fellow
- Karolinska Institute (2007)
Research
Overview
Medical Research Interests
Autoimmune Diseases
ORCID
0000-0002-9719-0028
Research at a Glance
Yale Co-Authors
Frequent collaborators of Margarita Dominguez-Villar's published research.
Kevin O'Connor, PhD
Richard Nowak, MD, MS
Publications
2024
Sphingosine‐1‐Phosphate Signalling Inhibition Suppresses Th1‐Like Treg Generation by Reversing Mitochondrial Uncoupling
Coulombeau R, Selck C, Giang N, Al‐Mohammad A, Ng N, Maher A, Argüello R, Scalfari A, Varley J, Nicholas R, Dominguez‐Villar M. Sphingosine‐1‐Phosphate Signalling Inhibition Suppresses Th1‐Like Treg Generation by Reversing Mitochondrial Uncoupling. Immunology 2024 PMID: 39444366, DOI: 10.1111/imm.13870.Peer-Reviewed Original ResearchConceptsTh1-like TregsSphingosine-1-phosphateSuppressive functionMitochondrial uncouplingSignaling inhibitionIncreased suppressive functionMultiple sclerosisTreg plasticityTreg reprogrammingTreg frequencyTreg generationTregsAutoimmune conditionsExpression of genesInflammatory environmentMS patientsS1P inhibitionFTY720Defective functionS1PMTORC1 signalingInhibitionReprogrammingCell Culture Evaluation Hints Widely Available HIV Drugs Are Primed for Success if Repurposed for HTLV-1 Prevention
Kalemera M, Maher A, Dominguez-Villar M, Maertens G. Cell Culture Evaluation Hints Widely Available HIV Drugs Are Primed for Success if Repurposed for HTLV-1 Prevention. Pharmaceuticals 2024, 17: 730. PMID: 38931397, PMCID: PMC11206710, DOI: 10.3390/ph17060730.Peer-Reviewed Original ResearchCitationsAltmetricConceptsAdult T-cell leukaemia/lymphomaIntegrase strand transfer inhibitorsNucleoside reverse transcriptase inhibitorsHTLV-1Reservoir of latently infected CD4+ T cellsDevelopment of adult T-cell leukaemia/lymphomaHIV-1Latently infected CD4+ T cellsHuman T-cell lymphotropic virus type 1Infected CD4+ T cellsCD4+ T cellsHTLV-1 endemic areasAssociated with poor prognosisHTLV-1-associated pathologiesAntiretroviral therapy prescriptionT-cell leukaemia/lymphomaStrand transfer inhibitorsHTLV-1 infectionHTLV-1 transmissionReverse transcriptase inhibitorsShorter overall survivalVirus type 1HIV pillsOverall survivalHIV therapyHTLV-1 induces an inflammatory CD4+CD8+ T cell population in HTLV-1–associated myelopathy
Maher A, Aristodemou A, Giang N, Tanaka Y, Bangham C, Taylor G, Dominguez-Villar M. HTLV-1 induces an inflammatory CD4+CD8+ T cell population in HTLV-1–associated myelopathy. JCI Insight 2024, 9: e173738. PMID: 38193535, PMCID: PMC10906466, DOI: 10.1172/jci.insight.173738.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHTLV-1-associated myelopathyDP T cellsT cellsHTLV-1Double-positive T cellsAdult T-cell leukemiaT cell populationsT-cell tropismHTLV-1 infectionHuman T-cell leukemia virus type 1Virus type 1T-cell leukemiaCXCR3 expressionPreferential CD4Asymptomatic infectionCNS pathologyIL-6Asymptomatic carriersInflammatory diseasesCytotoxic phenotypeCell leukemiaCell tropismType 1CD4Cell populations
2014
Pathogenic Antigen-Specific Th17 Cells Drive Autoimmunity Myasthenia Gravis (P1.059)
Cao Y, Dominguez-Villar M, Amezquita R, Liu S, Kleinstein S, Goldstein J, Nowak R, O'Connor K. Pathogenic Antigen-Specific Th17 Cells Drive Autoimmunity Myasthenia Gravis (P1.059). Neurology 2014, 82 DOI: 10.1212/wnl.82.10_supplement.p1.059.Peer-Reviewed Original Research
News
Get In Touch
Contacts
Academic Office Number